Cabaletta Bio, Inc.

Historical 13F Holders

Symbol
CABA
CUSIP
12674W109
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 12674W109 since 12/18/2024, largest first.

Filer % of Class Filed
T. Rowe Price Investment Management, Inc. 13G/A 13.1% 11/6/2026
Event 10/31/2026
Jennison Associates LLC 13G/A 11.4% 6/4/2026
Event 5/29/2026
Prudential Financial Inc 13G/A 11.4% 6/5/2026
Event 5/31/2026
Bain Capital Life Sciences Opportunities III, LP 13G/A 9.6% 11/16/2026
Event 9/30/2026
Adage Capital Management, L.P. 13G/A
8.4% 8/12/2026
Event 6/30/2026
BlackRock, Inc. 13G/A 7.7% 10/27/2026
Event 9/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (8)
Alyeska Investment Group, L.P. 13G/A
4.7% 2/17/2026
Event 12/31/2025
Norges Bank 13G/A 4.0% 11/12/2026
Event 9/30/2026
Vanguard Group Inc 13G/A 3.8% 7/29/2025
Event 6/30/2025
Vanguard Capital Management LLC 13G/A 3.8% 10/30/2026
Event 9/30/2026
Citadel Advisors LLC 13G/A
3.4% 11/14/2025
Event 9/30/2025
Nichtberger Steven 13G/A 3.3% 8/11/2025
Event 6/30/2025
Cormorant Asset Management, LP 13G/A
2.7% 11/16/2026
Event 9/30/2026
Millennium Management LLC 13G/A
1.3% 7/23/2026
Event 6/30/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 165 189 M $361M
2026 Q2 142 158 M $490M
2026 Q1 112 84.7 M $228M
2025 Q4 95 80.3 M $176M
2025 Q3 76 69.2 M $162M
2025 Q2 87 72.8 M $111M
2025 Q1 94 36.3 M $50.3M
2024 Q4 111 38.4 M $87.2M
2024 Q3 121 48.0 M $227M
2024 Q2 144 50.8 M $380M
2024 Q1 162 51.1 M $871M
2023 Q4 130 48.5 M $1.10B
2023 Q3 99 40.9 M $623M
2023 Q2 87 36.4 M $470M
2023 Q1 73 24.7 M $204M
2022 Q4 62 19.9 M $184M
2022 Q3 57 11.9 M $7.76M
2022 Q2 56 16.8 M $17.8M
2022 Q1 63 18.2 M $36.9M
2021 Q4 67 18.2 M $68.9M
2021 Q3 62 17.4 M $211M
2021 Q2 64 15.8 M $135M
2021 Q1 70 16.2 M $180M
2020 Q4 56 16.2 M $202M
2020 Q3 55 16.4 M $177M
2020 Q2 53 16.4 M $183M
2020 Q1 42 16.0 M $117M
2019 Q4 41 16.3 M $227M